Skip to main content
HairCited

Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups.

Lili Legiawati, Irma Bernadette S Sitohang, Shannaz Nadia Yusharyahya, Sondang P Sirait, Endi Novianto et al.
Other Archives of dermatological research 2025 3 citações
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D40021536'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo de Estudo
Controlled Clinical Trial
Tamanho da Amostra
60
População
Patients with androgenetic alopecia
Duração
12 weeks
Intervenção
Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups. Injections at week 0, 4, 8
Comparador
Minoxidil only and secretome only
Desfecho Primário
Hair growth parameters at week 12
Direção do Efeito
Positive
Risco de Viés
Moderate

Abstract

Androgenetic alopecia is one of the most common cause of hair loss disorder. This hereditary and androgen-dependent disorder tends to progress into partial or even complete baldness Several therapeutic options are now available for AGA, including conventional medications such as finasteride, dutasteride, and minoxidil. However, side effects of these medications are also commonly reported. The use of adipose derived stem cells and their secreted bioactive molecules, "secretome" has gained attention which could produce many effects for hair growth promotion and has been proven in clinical trials. This study aims to compare the effectiveness and safety of with minoxidil in androgenetic alopecia cases. 60 subjects were divided into three treatment groups (minoxidil only, secretome only, and combination of both) and were given intervention on week 0, 4, and 8. All subjects were evaluated by physical examination, photography, trichoscopy, and trichoscan until week 12. All groups showed a statistically significant improvement (p < 0.05) on hair growth parameters with the best improvement observed on week 12. The combination group had the best improvement substantially on hair growth parameters. Side effects are minimum and reported by the subjects in minoxidil group. Clinicaltrials.gov, NCT06066827. Registered 05 October 2023, Retrospectively. https://register.clinicaltrials.gov/prs/app/template/Home.vm?uid=U0004ES6_ts=7_sid=S000DOK9_cx=-igh2d .

Resumo Rápido

This study aims to compare the effectiveness and safety of with minoxidil in androgenetic alopecia cases and found the combination group had the best improvement substantially on hair growth parameters.

Used In Evidence Reviews

Similar Papers